Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Transplant beats bortezomib-based therapy for MM, but questions remain

Publish date:: May 7, 2020

Key clinical point: Autologous hematopoietic stem-cell transplantation (HSCT) beat bortezomib-based intensification therapy in newly diagnosed myeloma, though more research is needed to determine the optimal upfront strategy in eligible patients.

Major finding: Median progression-free survival was 56.7 months for HSCT, compared to 41.9 months for bortezomib-based therapy (P = .0001).

Study details: Results of EMN02/HO95, a multicenter, randomized, open-label, phase 3 study including 1,503 MM patients up to 65 years of age.

Disclosures: The lead author reported receiving honoraria from multiple pharmaceutical companies, and is a member of speakers bureaus for Janssen and Celgene. Dr. Nadeem and Dr. Ghobrial reported serving on the advisory boards of multiple pharmaceutical companies.

Citation:

Cavo M et al. Lancet Haematol. 2020 Apr 30. doi: 10.1016/S2352-3026(20)30099-5.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Multiple Myeloma

Caregiver burden of outpatient ASCT for multiple myeloma comparable with inpatient transplant,

Study found dual-targeted CAR T highly active against relapsed/refractory multiple myeloma,

Durable responses with anti-BCMA CAR T-cell for multiple myeloma,

Circulating miRNA could be a potential biomarker for early diagnosis of MM,